Glucagonoma history and symptoms: Difference between revisions

Jump to navigation Jump to search
Line 34: Line 34:
* Some patients do not present with hormonal symptoms but present with metastatic symptoms in other organs and mainly the liver.  
* Some patients do not present with hormonal symptoms but present with metastatic symptoms in other organs and mainly the liver.  
**These symptoms include [[jaundice]], [[edema]], and [[abdominal pain]].  
**These symptoms include [[jaundice]], [[edema]], and [[abdominal pain]].  
**There is usually high level of substances such as chromogranins, enolase, pancreatic polypeptide, and ghrelin in patients with metastses.
**There is usually high level of substances such as [[chromogranins]], [[enolase]], [[pancreatic polypeptide]], and [[ghrelin]] in patients with metastses.


* Some tumors can develop additional syndromes subsequently due to secretion of more than one hormone.<gallery>Image:Close-up view of well demarcated erythematous plaques, with fragile vesicles on gluteal area..jpg|Close-up view of well demarcated erythematous plaques, with fragile vesicles on gluteal area<ref name="pmid25029913">{{cite journal| author=Wu SL, Bai JG, Xu J, Ma QY, Wu Z| title=Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor. | journal=World J Surg Oncol | year= 2014 | volume= 12 | issue=  | pages= 220 | pmid=25029913 | doi=10.1186/1477-7819-12-220 | pmc=PMC4105234 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25029913  }} </ref>
* Some tumors can develop additional syndromes subsequently due to secretion of more than one hormone.<gallery>Image:Close-up view of well demarcated erythematous plaques, with fragile vesicles on gluteal area..jpg|Close-up view of well demarcated erythematous plaques, with fragile vesicles on gluteal area<ref name="pmid25029913">{{cite journal| author=Wu SL, Bai JG, Xu J, Ma QY, Wu Z| title=Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor. | journal=World J Surg Oncol | year= 2014 | volume= 12 | issue=  | pages= 220 | pmid=25029913 | doi=10.1186/1477-7819-12-220 | pmc=PMC4105234 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25029913  }} </ref>

Revision as of 18:26, 11 October 2017

Glucagonoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Glucagonoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucagonoma history and symptoms On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucagonoma history and symptoms

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucagonoma history and symptoms

CDC on Glucagonoma history and symptoms

Glucagonoma history and symptoms in the news

Blogs on Glucagonoma history and symptoms

Directions to Hospitals Treating Glucagonoma

Risk calculators and risk factors for Glucagonoma history and symptoms

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2], Mohammed Abdelwahed M.D[3]

Overview

Symptoms of glucagonoma include necrolytic migratory erythema, weight loss, glucose intolerance, cheilosis, stomatitis, diarrhea, polyuria, and polydipsia. A positive family history of multiple endocrine neoplasia type 1 may be present.

History

  • When evaluating a patient for glucagonoma, you should take a detailed history of the presenting symptom (onset, duration, and progression), other associated symptoms, and a thorough review of past medical history.
  • Other specific areas of focus when obtaining the history include the family history of predisposing genetic disorders such as multiple endocrine neoplasia type 1.

Symptoms

Common symptoms of glucagonoma

Common symptoms of glucagonoma include:[1][2][3][4]

Less common symptoms include:

Less common symptoms of glucagonoma include:[5][6][7]

  • Some tumors can develop additional syndromes subsequently due to secretion of more than one hormone.
  • Close-up view of well demarcated erythematous plaques, with fragile vesicles on gluteal area[8]

    Close-up view of well demarcated erythematous plaques, with fragile vesicles on gluteal area[8]

  • Necrolytic migratory erythema with erosion and crust formation[9]

    Necrolytic migratory erythema with erosion and crust formation[9]

  • Skin eruptionsA) Erythema, scaling, erosions and crusts on the face B) Intense erythema with crusted erosions at perineum C) Polycyclic migratory lesions with scaling advancing borders at groin folds D) Glossitis[10]

    Skin eruptionsA) Erythema, scaling, erosions and crusts on the face B) Intense erythema with crusted erosions at perineum C) Polycyclic migratory lesions with scaling advancing borders at groin folds D) Glossitis[10]

References

  1. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996). "The glucagonoma syndrome. Clinical and pathologic features in 21 patients". Medicine (Baltimore). 75 (2): 53–63. PMID 8606627.
  2. Wilkinson DS (1973). "Necrolytic migratory erythema with carcinoma of the pancreas". Trans St Johns Hosp Dermatol Soc. 59 (2): 244–50. PMID 4793623.
  3. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996). "The glucagonoma syndrome. Clinical and pathologic features in 21 patients". Medicine (Baltimore). 75 (2): 53–63. PMID 8606627.
  4. Stacpoole PW (1981). "The glucagonoma syndrome: clinical features, diagnosis, and treatment". Endocr Rev. 2 (3): 347–61. doi:10.1210/edrv-2-3-347. PMID 6268399.
  5. Stacpoole PW (1981). "The glucagonoma syndrome: clinical features, diagnosis, and treatment". Endocr Rev. 2 (3): 347–61. doi:10.1210/edrv-2-3-347. PMID 6268399.
  6. Chang-Chretien K, Chew JT, Judge DP (2004). "Reversible dilated cardiomyopathy associated with glucagonoma". Heart. 90 (7): e44. doi:10.1136/hrt.2004.036905. PMC 1768315. PMID 15201270.
  7. Cheema A, Weber J, Strosberg JR (2012). "Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes". Ann Surg Oncol. 19 (9): 2932–6. doi:10.1245/s10434-012-2285-7. PMID 22350605.
  8. Wu SL, Bai JG, Xu J, Ma QY, Wu Z (2014). "Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor". World J Surg Oncol. 12: 220. doi:10.1186/1477-7819-12-220. PMC 4105234. PMID 25029913.
  9. Fang S, Li S, Cai T (2014). "Glucagonoma syndrome: a case report with focus on skin disorders". Onco Targets Ther. 7: 1449–53. doi:10.2147/OTT.S66285. PMC 4140234. PMID 25152626.
  10. Erdas E, Aste N, Pilloni L, Nicolosi A, Licheri S, Cappai A; et al. (2012). "Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association?". BMC Cancer. 12: 614. doi:10.1186/1471-2407-12-614. PMC 3543729. PMID 23259638.